Table 3:

Carboplatin pharmacokinetics, n=15.

Patient ID	CmaxPF (µg/mL)	CmaxPL (µg/mL)	T½PF (min)	T½PL (min)	AUC90PF (min × µg/mL)	AUC90PL (min × µg/mL)	AUCtotalPL (min × µg/mL)	AUC ratioa
1	365	23	123	131	25,865	1,572	5,361	16.5
2	349	27	92	153	22,920	1,956	6,427	11.7
3	279	21	190	170	21,643	1,431	5,120	15.1
4	595	39	63	162	34,122	2,695	10,028	12.7
5	360	32	102	170	24,953	2,032	8,805	12.3
6	407	27	132	173	28,909	1,682	6,451	17.2
7	290	32	106	140	19,956	2,162	6,449	9.2
8	293	29	115	181	20,967	1,955	8,014	10.7
9	297	33	108	147	20,667	2,134	7,330	9.7
10	322	29	96	164	21,813	1,928	6,936	11.3
11	393	29	109	154	26,916	1,928	6,328	14.0
12	400	28	112	182	28,384	1,746	7,310	16.3
13	354	28	98	193	24,304	1,794	6,865	13.5
14	297	32	76	157	17,671	2,384	7,662	7.4
15	318	27	90	134	20,225	1,828	5,850	11.1
Meanb	348	29	104	160	23,612	1,926	6,892	12.3
CI95%	312–387	27–31	91–120	150–170	21,446–25,997	1,764–2,102	6,247–7,604	10.8–14.0
Range	279–595	21–39	63–190	131–193	17,671–34,122	1,431–2,695	5,120–10,028	7.4–17.2
IQR	297–393	27–32	92–115	147–173	20,667–26,916	1,746–2,134	6,328–7,662	10.7–15.1

Cmax, maximum concentration; PF, perfusate; PL, plasma; T½, terminal half-life; AUC90, area under concentration-time curve during perfusion time; AUCtotal, area under concentration-time curve for total sampling period; CI_95%, 95% confidence interval; IQR, interquartile range.

^aAUC90PF/AUC90PL.

^bGeometric mean.